BeOne Medicines Q2 Revenue Surges 30% to $1.7B, BRUKINSA Hits $1.2B
ONC sits 32% above its 52-week low of $253.948.
Summary
BeOne Medicines reported Q2 2026 revenue of $1.7 billion, up 30% year-over-year, with BRUKINSA sales reaching $1.2 billion. Net income surged to $237 million, and the company held $5.1 billion in cash.
Key Events · Earnings and Guidance · ONC
-
Revenue Jumps 30% to $1.7B
Driven by BRUKINSA sales of $1.248 billion (up 31%) and TEVIMBRA sales of $228.5 million (up 18%), total Q2 2026 revenue reached $1.705 billion, compared with $1.315 billion in Q2 2025.
-
Net Income More Than Doubles
GAAP net income came in at $237 million, or $2.05 per diluted ADS, a sharp rise from $94.3 million, or $0.84 per diluted ADS, in the prior-year quarter. Non-GAAP diluted EPS was $3.84.
-
Cash Position Strengthens to $5.1B
As of June 30, 2026, cash and cash equivalents grew to $5.098 billion from $4.548 billion at year-end 2025, providing ample runway for pipeline investment and debt service.
-
New Insider Trading Plans Adopted
General Counsel Chan Lee adopted a 10b5-1 plan covering up to 9,353 ADSs plus RSU-related shares, and co-founder Dr. Xiaodong Wang adopted a plan for up to 131,370 ADSs, continuing a pattern of insider selling.
Analysis · ONC · Life Sciences
A standout quarter underscores BeOne Medicines' transformation into a profitable, cash-generating oncology leader. Total revenue jumped 30% to $1.7 billion, propelled by the flagship BTK inhibitor BRUKINSA, which alone contributed $1.2 billion—a 31% increase. The bottom line swung dramatically to a GAAP net income of $237 million from $94 million a year ago, and the company closed the quarter with $5.1 billion in cash. While the operational momentum is strong, investors should also weigh the newly disclosed 10b5-1 trading plans from the General Counsel and a co-founder, which add to a pattern of insider selling.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 45.6% of the 241 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONC was trading at $335.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.9B. The 52-week trading range was $253.95 to $385.22. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.